• linkedin
  • Increase Font
  • Sharebar

    Honors celebrate research, future generation in retina


    IOP and anti-VEGFs

    The overall leading research presentation was on the real-world effect of anti-vascular endothelial growth factor (VEGF) injections on IOP, presented by Elizabeth Atchinson, MD, a senior fellow at Rush University and Illinois Retina Associates. Dr. Atchinson used the American Academy of Ophthalmology (AAO) IRIS Registry to evaluate how anti-VEGF injections’ effect on IOP in the treated eye compared with the patient’s untreated fellow eye.

    The primary outcome was the IOP change from baseline, and considered a clinically significant IOP rise as an increase of at least 6 mm Hg with an IOP >21 mm Hg among treatment-naïve eyes, or those previously diagnosed with age-related macular degeneration (AMD). Subjects could receive any of the commonly used anti-VEGFs (aflibercept, bevacizumab, or ranibizumab).

    In 2016, there were 4,548 aflibercept injections, 13,349 bevacizumab injections, and 5,879 ranibizumab injections (60% of which were received by females) recorded in the IRIS Registry. The AMD eyes received about 8 to 9 injections, and treatment-naïve eyes received about 6 to 9 injections.

    In the aflibercept and bevacizumab eyes, there was a statistically significant decrease in IOP between the treated and fellow eyes when evaluated by the anti-VEGF drug. There was a statistically significant increase in IOP between treated and untreated eyes when evaluated by disease state.

    “These rates were lower than seen in clinical trials,” Dr. Atchinson said. “In our real-world dataset, there was a 2.6% increase in IOP over 1.8 years, compared with 8% in VIEW and 23% in MARINA and ANCHOR.”

    More importantly, these real-world data increases were not clinically significant.

    This year’s remaining top five finalists were: Xuejing (Jing) Chen, MD; Parisi Enami-Naeini, MD, PhD; Malvika Arya, BS; and Peter Tang, MD, PhD.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';